Jesse Shefferman
Known title: CEO and PresidentCIK: 0001799167
Jesse Shefferman's purchase track record
Jesse Shefferman has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/11/2022 | TARA | $35K | -28.1% | -2.5% | -3.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| TARA | ▼ Sell | Gift | 14,000 | $0 | 6/30/2026 | View on chart |
| TARA | ▼ Sell | Gift | 7,000 | $0 | 6/30/2026 | View on chart |
| TARA | ▼ Sell | Gift | 4,000 | $0 | 6/30/2026 | View on chart |
| TARA | ▼ Sell | Gift | 5,000 | $0 | 6/30/2026 | View on chart |
| TARA | ▲ Buy | Option Exercise | 215,687 | $412K | 6/29/2026 | View on chart |
| TARA | ▼ Sell | Open Market | 215,687 | $882K | 6/29/2026 | View on chart |
| TARA | ▼ Sell | Tax Withholding | 8,732 | $58K | 1/26/2026 | View on chart |
| TARA | ▼ Sell | Tax Withholding | 16,322 | $91K | 1/20/2026 | View on chart |
| TARA | ▲ Buy | Grant | 87,000 | $0 | 1/16/2026 | View on chart |
| TARA | ▼ Sell | Gift | 10,200 | $0 | 6/27/2025 | View on chart |
| TARA | ▼ Sell | Gift | 3,367 | $0 | 6/27/2025 | View on chart |
| TARA | ▼ Sell | Gift | 1,700 | $0 | 6/26/2025 | View on chart |
| TARA | ▼ Sell | Gift | 3,400 | $0 | 6/26/2025 | View on chart |
| TARA | ▼ Sell | Gift | 300,000 | $0 | 6/24/2025 | View on chart |
| TARA | ▲ Buy | Grant | 65,000 | $0 | 1/24/2025 | View on chart |
| TARA | ▼ Sell | Tax Withholding | 15,469 | $74K | 1/21/2025 | View on chart |
| TARA | ▼ Sell | Tax Withholding | 6,479 | $40K | 1/3/2025 | View on chart |
| TARA | ▼ Sell | Gift | 5,263 | $0 | 8/28/2024 | View on chart |
| TARA | ▼ Sell | Gift | 3,300 | $0 | 8/28/2024 | View on chart |
| TARA | ▲ Buy | Grant | 59,000 | $0 | 1/19/2024 | View on chart |
| TARA | ▼ Sell | Tax Withholding | 7,803 | $15K | 1/19/2024 | View on chart |
| TARA | ▼ Sell | Tax Withholding | 5,746 | $14K | 1/10/2024 | View on chart |
| TARA | ▼ Sell | Tax Withholding | 5,840 | $13K | 1/3/2024 | View on chart |
| TARA | ▼ Sell | Gift | 7,420 | $0 | 6/27/2023 | View on chart |
| TARA | ▼ Sell | Gift | 1,890 | $0 | 6/23/2023 | View on chart |
| TARA | ▲ Buy | Grant | 51,300 | $0 | 1/19/2023 | View on chart |
| TARA | ▼ Sell | Tax Withholding | 5,855 | $18K | 1/10/2023 | View on chart |
| TARA | ▼ Sell | Tax Withholding | 6,604 | $18K | 1/3/2023 | View on chart |
| TARA | ▲ Buy | Open Market | 9,065 | $35K | 8/11/2022 | View on chart |
| TARA | ▼ Sell | Tax Withholding | 5,080 | $32K | 1/10/2022 | View on chart |
| TARA | ▲ Buy | Grant | 42,300 | $0 | 1/3/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Protara Completes THRIVE-3 Trial Enrollment
Protara Therapeutics has finished enrolling patients in the Phase 2b dose confirmation phase of its THRIVE-3 registrational trial for IV Choline Chloride. This milestone marks a significant step in the development process for the company's lead product. The stock is currently trading near its 52-week low, reflecting the ongoing uncertainty surrounding the upcoming trial results.
Protara Completes THRIVE-3 Trial Enrollment. Protara Therapeutics has finished enrolling patients in the Phase 2b dose confirmation phase of its THRIVE-3 registrational trial for IV Choline Chloride. This milestone marks a significant step in the development process for the company's lead product. The stock is currently trading near its 52-week low, reflecting the ongoing uncertainty surrounding the upcoming trial results.